The recommended dosage of lurbinectedin in combination with immunotherapy is not explicitly mentioned in the provided sources. However, we can gather some information about lurbinectedin and its use in combination with immunotherapy.
Lurbinectedin is a novel anticancer drug that has shown promising results in clinical trials for the treatment of various types of cancer. It works by inhibiting the transcription process in cancer cells, leading to their death [3]. According to the Drug Patent Watch website, lurbinectedin is currently undergoing clinical trials and does not have an approved dosage [1].
In terms of combining lurbinectedin with immunotherapy, the National Cancer Institute (NCI) provides information on a clinical trial (NCI-2022-10037) that investigates the combination of lurbinectedin with the immunotherapy drug pembrolizumab in patients with advanced solid tumors [2]. The trial aims to determine the safety, tolerability, and efficacy of this combination. However, the specific dosage of lurbinectedin in this trial is not mentioned in the provided source.
To obtain more detailed information about the recommended dosage of lurbinectedin in combination with immunotherapy, it is advisable to consult with a healthcare professional or clinical trial investigator. They can provide the most up-to-date and accurate information regarding the dosage and administration of lurbinectedin in combination with immunotherapy.
In conclusion, while the recommended dosage of lurbinectedin in combination with immunotherapy is not explicitly mentioned in the provided sources, it is important to consult with healthcare professionals or clinical trial investigators for the most accurate and up-to-date information.
Sources:
[1] Drug Patent Watch. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Cancer Institute. (n.d.). Clinical Trials: NCI-2022-10037. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-10037
[3] Zaman, G. J. R., Lankheet, N. A. G., van Tellingen, O., Beijnen, J. H., & Schellens, J. H. M. (2021). Mechanisms of Resistance in Lurbinectedin Clinical Trials. Cancers, 13(11), 2691. doi: 10.3390/cancers13112691